Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges

PURPOSE: Soft tissue and bone sarcomas are rare malignancies that exhibit significant pathologic and molecular heterogeneity. Deregulation of the CDKN2A-CCND-CDK4/6-retinoblastoma 1 (Rb) pathway is frequently observed in about 25% of unselected sarcomas and is pathognomonic for specific sarcoma subt...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Jocelyn Y., Seligson, Nathan D., Hays, John L., Miles, Wayne O., Chen, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
REVIEW ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820917/
https://www.ncbi.nlm.nih.gov/pubmed/35108033
http://dx.doi.org/10.1200/PO.21.00211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820917/
https://www.ncbi.nlm.nih.gov/pubmed/35108033
http://dx.doi.org/10.1200/PO.21.00211

Ejemplares similares